Evidence map›Paper›PMID 42747649›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).

Toshifumi Yamaguchi, Ryohei Kawabata, Yusuke Akamaru, Hidekazu Hirano, Keijiro Sugimura, Yasuhiro Miyazaki, Yoshihiro Kakeji, Yosuke Kito, Takashi Nomura, Takeshi Kawakami and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Toshifumi YamaguchiCancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
Ryohei KawabataDepartment of Surgery, Sakai City Medical Center, 1-1-1 Ebaraji-Cho, Sakai-Shi, Osaka, 272-1199, Japan.
Yusuke AkamaruDepartment of Gastroenterological Surgery, Osaka Rosai Hospital, 1179-3 Nakasonecho, Kita-Ku, Sakai-Shi, Osaka, 591-8025, Japan.
Hidekazu HiranoDepartment of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Keijiro SugimuraDepartment of Surgery, Kansai Rosai Hospital, 3-1-69 Inabaso, Amagasaki, Hyogo, 660-8511, Japan.
Yasuhiro MiyazakiDepartment of Surgery, Osaka General Medical Center, 3-1-56 Bandaihigashi, Sumiyoshi-Ku, Osaka City, Osaka, 558-8558, Japan.
Yoshihiro KakejiDivision of Gastrointestinal Surgery, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.
Yosuke KitoDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, 2-1 Kuratsuki Higashi, Kanazawa City, Ishikawa Prefecture, 920-8530, Japan.
Takashi NomuraDepartment of Surgery, Yamagata Prefectural Central Hospital, 1800 Aoyanagi, Yamagata-Shi, Yamagata, 990-2292, Japan.
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Sunto-Gun, Shizuoka, 411-8777, Japan.
Masahiro TanemuraDepartment of Surgery, Rinku General Medical Center, 2-23 Rinku Orai-Kita, Izumisano-City, Osaka, 598-8577, Japan.
Atsushi TakenoDepartment of Surgery, NHO Osaka National Hospital, 2-1-14 Hoenzaka, Chuo-Ku, Osaka, Osaka, 540-0006, Japan.
Hiroyuki OkudaDepartment of Medical Oncology, Keiyukai Sapporo Hospital, 1-1, Minami 9-Chome, Hondori, Shiroishi-Ku, Sapporo-Shi, Hokkaido, 003-0026, Japan.
Tomohiro MatsushimaDepartment of Gastroenterology, Saitama Cancer Center, 818 Komuro, Ina-Machi, Kitaadati-Gun, Saitama, 362-0806, Japan.
Toshio ShimokawaDepartment of Biostatistics, Faculty of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama-Shi, 641-8509, Japan.
Yukinori KurokawaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, 2-2 Yamadaoka, Suita, 565-0871, Japan.
Shunji EndoDepartment of Digestive Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, 4-6-1, Shirokanedai, Minato-Ku, Tokyo, 108-8639, Japan. nboku@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-1438-707X
Taroh SatohCenter for Cancer Genomics and Precision Medicine, The University of Osaka Hospital, 2-2 Yamadaoka, Suita, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who experienced early recurrence during or within 6 months after DS adjuvant chemotherapy.

methodsThis prospective, open-label, multicenter phase II trial enrolled eligible patients treated at 25 centers of the Osaka Gastrointestinal Cancer Chemotherapy Study Group in Japan. Patients received ramucirumab (8 mg/kg) and irinotecan (150 mg/m

resultsBetween November 2019 and July 2023, 43 patients were enrolled, and 39 were included in the analysis after excluding three ineligible patients and one who did not initiate protocol treatment. The median OS was 15.9 months (95% CI: 8.8-42.0; p = 0.003). The median PFS was 5.5 months (95% CI: 3.9-8.1), and the ORR was 38.5%. Grade  ≥ 3 adverse events, including neutropenia (25.6%) and hypertension (25.6%), were observed in more than 20% of patients.

conclusionRamucirumab plus irinotecan demonstrated promising efficacy and manageable toxicity in patients with early recurrence of GC following adjuvant DS therapy.

trial registrationThis study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs05119071, October 6, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs051190071 ).

Indexed as

DocetaxelEarly recurrenceGastric cancerIrinotecanRamucirumabS-1

Identifiers

PMID42747649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.